Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease
First Online: 11 April 2006 Received: 15 March 2005 Accepted: 20 December 2005 DOI:
10.1007/s00702-006-0442-5 Cite this article as: Müller, T., Erdmann, C., Muhlack, S. et al. J Neural Transm (2006) 113: 1441. doi:10.1007/s00702-006-0442-5 Summary.
Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD). Objectives were to determine the clinical response after EN addition and the plasma degradation of LD and 3-O-methyldopa [3-OMD]. Not optimum treated hospitalised patients with Parkinson’s disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t.i.d.) within a standardised setting. We scored motor symptoms and measured LD- and 3-OMD levels on both days at fixed moments. Motor impairment significant better improved probably due to significant higher maximum concentrations [C
max] and computed area under the curve values of LD levels during the LD/CD/EN condition. Time to C max of LD was significantly delayed after the first two LD/CD/EN intakes. An impact of EN on 3-OMD levels appeared. A possibly augmented LD absorption and a prolonged LD metabolism after EN supplementation may contribute to a more continuous LD delivery to the brain. Keywords: Levodopa, 3-O-methyldopa, entacapone. References Benetello, P, Furlanut, M, Fortunato, M, Pea, F, Baraldo, M 1997 Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association Pharmacol Res 35 313 315 PubMed CrossRef Google Scholar Evans, MA, Broe, GA, Triggs, EJ, Cheung, M, Creasey, H, Paull, PD 1981 Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient Neurology 31 1288 1294 PubMed Google Scholar Fahn, S, Oakes, D, Shoulson, I, Kieburtz, K, Rudolph, A, Lang, A, Olanow, CW, Tanner, C, Marek, K 2004 Levodopa and the progression of Parkinson’s disease N Engl J Med 351 2498 2508 PubMed CrossRef Google Scholar Goetz, CG, LeWitt, PA, Weidenman, M 2003 Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program Mov Disord 18 1455 1458 PubMed CrossRef Google Scholar Hughes, AJ, Daniel, SE, Kilford, L, Lees, AJ 1992 Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181 184 PubMed CrossRef Google Scholar Kaakkola, S, Teravainen, H, Ahtila, S, Rita, H, Gordin, A 1994 Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients Neurology 44 77 80 PubMed Google Scholar Koller, W, Guarnieri, M, Hubble, J, Rabinowicz, AL, Silver, D 2004 An open-label evaluation of the tolerability and safety of Stalevo (R) (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off J Neural Transm 112 221 230 PubMed CrossRef Google Scholar Kurlan, R, Rothfield, KP, Woodward, WR, Nutt, JG, Miller, C, Lichter, D, Shoulson, I 1988 Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility Neurology 38 419 421 PubMed Google Scholar Männisto, PT, Kaakkola, S, Nissinen, E, Linden, IB, Pohto, P 1988 Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase Life Sci 43 1465 1471 PubMed CrossRef Google Scholar Muhlack, S, Woitalla, D, Welnic, J, Twiehaus, S, Przuntek, H, Müller, T 2004 Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease Neurosci Lett 363 284 287 PubMed CrossRef Google Scholar Müller, T, Voss, B, Hellwig, K, Josef, SF, Schulte, T, Przuntek, H 2004 Treatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic CNS Drugs 18 105 111 PubMed CrossRef Google Scholar Müller, T, Woitalla, D, Schulz, D, Peters, S, Kuhn, W, Przuntek, H 2000 Tolcapone increases maximum concentration of levodopa J Neural Transm 107 113 119 PubMed CrossRef Google Scholar Murata, M, Kanazawa, I 1997 Effects of chronic levodopa therapy on dopa pharmacokinetics Eur Neurol 38 50 55 PubMed Google Scholar Nissinen, E, Tuominen, R, Perhoniemi, V, Kaakkola, S 1988 Catechol-O-methyltransferase activity in human and rat small intestine Life Sci 42 2609 2614 PubMed CrossRef Google Scholar Nutt, JG 1998 Catechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease Lancet 351 1221 1222 PubMed CrossRef Google Scholar Nutt, JG 2000 Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 55 S33 S37 PubMed Google Scholar Olanow, CW, Kieburtz, K, Stern, M, Watts, R, Langston, JW, Guarnieri, M, Hubble, J 2004 Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease Arch Neurol 61 1563 1568 PubMed CrossRef Google Scholar Papavasiliou, PS, Cotzias, GC, Duby, SE, Steck, AJ, Fehling, C, Bell, MA 1972 Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor N Engl J Med 286 8 14 PubMed Google Scholar Poewe, W 2004 The role of COMT inhibition in the treatment of Parkinson’s disease Neurology 62 S31 S38 PubMed CrossRef Google Scholar Schultz, E, Tarpila, S, Backstrom, AC, Gordin, A, Nissinen, E, Pohto, P 1991 Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone Eur J Clin Pharmacol 40 577 580 PubMed Google Scholar Smith, LA, Jackson, MJ, Hansard, MJ, Maratos, E, Jenner, P 2003 Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure Mov Disord 18 487 495 PubMed CrossRef Google Scholar Waller, DG, Roseveare, C, Renwick, AG, Macklin, B, George, CF 1991 Gastric emptying in healthy volunteers after multiple doses of levodopa Br J Clin Pharmacol 32 691 695 PubMed Google Scholar